Antibodies for
Immunohistochemistry
CA19-9 (121SLE)
Mouse Monoclonal Antibody
Cat. No. Description
Volume
45692 IMPATH CA19-9 RTU M (121SLE)
50 Tests
44212 CA19-9 RTU M (121SLE)
7 ml Ready To Use
44448 CA19-9 0,1 M (121SLE)
100 µl liquid Concentrated
44449 CA19-9 1 M (121SLE)
1 ml liquid Concentrated
Product Specifications
Designation
IVD
Reactivity
Paraffin
Visualization
Cytoplasmic
Control
Colon
Stability
Up to 36 mo. at 2-8°C
Isotype
IgM
Manual Protocol*
• Pretreatment: Heat Induced Epitope
Retrieval (HIER)
• Primary Antibody Incubation Time:
10-30min @ 25-37°C
• 2-step polymer detection
*Please refer to product insert for complete protocol.
ImPath Protocol*
• Dewax: Dewax Solution 2 (DS2)
• Pretreatment: Retrieval Solution pH 9.0
(TR1) 32min @ 98-103°C
• Primary Antibody Incubation Time:
10-90min @ 25-37°C
• HRP Polymer (Universal) or AP Polymer
(Universal) for 12 min
*Please refer to product insert for complete protocol.
Product Description
CA19-9 antigen is highly expressed in gastrointestinal (gastric, pancreatic, and colonic) adenocarcinomas and salivary gland mucoepidermoid
carcinomas. Anti-CA19-9 is usually not reactive with breast, kidney, and prostate carcinomas.
Colon vs. Ovarian Carcinoma
CA19-9 CK 7
CK 20
CEA CDX-2
Villin Ep-CAM WT1 CA-125 CK 5&6
Ovarian Carcinoma, Serous
+
+
-
+
-
+
+
+
+
-
Ovarian Carcinoma,
Mucinous
+
+
-
-
+
+
+
-
-
Ovarian Endometrioid Ca
+/-
+
-
-
-
+
+
+
-
Colon Carcinoma
+
-
+
+
+
+
+
-
-
-
Breast Carcinoma
CA19-9
CK 7
CK 20
ER/PR
CA15-3
p63
CD117
CK 5
Infiltrating Ductal
Carcinoma
-
+
-
+
+
-
-
-
Adenoid Cystic Carcinoma
+
+
-
-
+
+
+
+
Pancreas
CA19-9 Synapto-
physin
Chromo-
granin A Insulin Glucagon Gastrin MUC4 CD56 β-Catenin CK 19
Ductal Adenocarcinoma
+
-
-
-
-
-
+
-
+/-
+
Neuroendocrine Tumor
+/-
+
+
+/-
+/-
+/-
-
+
+
+/-
Solid Pseudopapillary
Tumor
-
+
-
-
-
-
+
+
-
Acinic Cell Carcinoma
-/+
-
-
-
-
-
-
+
+
Pancreatoblastoma
-
-
+
-
-
-
-
+
+
-
Colon vs. Prostate Adenocarcinoma
CA19-9
CDX-2
CK 20
CEA
PSA
P504s
Colon Adenocarcinoma
+
+
+
+
-
+
Prostate Adenocarcinoma
-
-
-
-
+
+
Reference
1. Gatalica Z, et al. Applied IHC. 1994; 2(3):205-211.
38
